

PHENYLUREA DERIVATIVE**Publication number:** JP2003192659**Publication date:** 2003-07-09**Inventor:** YURA TAKESHI; MOGI MUNEHITO; IKEGAMI YUKA; MASUDA TSUTOMU; KOKUBO TOSHIO; URBAHNS KLAUS; YOSHIDA NAGAHIRO; MARUMO MAKIKO; SHIROO MASAHIRO; TAJIMI MASAOMI; TAKESHITA KEISUKE; MORIWAKI TOSHIYA; TSUKIMI YASUHIRO**Applicant:** BAYER AG**Classification:**

- international: A61K31/17; A61K31/245; A61K31/277; A61K31/341; A61K31/36; A61K31/381; A61K31/403; A61K31/416; A61K31/4406; A61K31/4409; A61K31/451; A61K31/47; A61P9/00; A61P9/10; A61P13/02; A61P13/10; A61P19/02; A61P25/00; A61P25/02; A61P25/28; A61P29/00; A61P41/00; A61P43/00; C07C275/32; C07C275/34; C07C275/36; C07C275/38; C07C275/40; C07C275/42; C07C323/44; C07D209/88; C07D213/40; C07D213/75; C07D215/38; C07D231/56; C07D295/12; C07D307/52; C07D317/66; C07D333/20; C07D333/36; A61K31/17; A61K31/21; A61K31/275; A61K31/341; A61K31/357; A61K31/381; A61K31/403; A61K31/416; A61K31/4406; A61K31/4409; A61K31/451; A61K31/47; A61P9/00; A61P13/00; A61P19/00; A61P25/00; A61P29/00; A61P41/00; A61P43/00; C07C275/00; C07C323/00; C07D209/00; C07D213/00; C07D215/00; C07D231/00; C07D295/00; C07D307/00; C07D317/00; C07D333/00; (IPC1-7): C07C275/32; A61K31/17; A61K31/245; A61K31/277; A61K31/341; A61K31/36; A61K31/381; A61K31/403; A61K31/416; A61K31/4406; A61K31/4409; A61K31/451; A61K31/47; A61P9/00; A61P9/10; A61P13/02; A61P13/10; A61P19/02; A61P25/00; A61P25/02; A61P25/28; A61P29/00; A61P41/00; A61P43/00; C07C275/34; C07C275/36; C07C275/38; C07C275/40; C07C275/42; C07C323/44; C07D209/88; C07D213/40; C07D213/75; C07D215/38; C07D231/56; C07D295/12; C07D307/52; C07D317/66; C07D333/20; C07D333/36; C07M9/00

- european:

Application number: JP20010395032 20011226**Priority number(s):** JP20010395032 20011226[Report a data error here](#)**Abstract of JP2003192659**

PROBLEM TO BE SOLVED: To provide a drug containing a phenylnaphthylurea derivative or a salt thereof as an active ingredient.

SOLUTION: This drug contains a compound of general formula (I) (e.g. N-(3,4-dichlorophenyl)-N'-(2-(2-hydroxyethyl)phenyl)urea) as the active ingredient. This drug exhibits high activity as a VRI antagonist and is useful for preventing and treating diseases associated with VRI activity, especially for treating impending incontinence, bladder hyperactivity, chronic pain, neuropathic pain, postoperative pain, chronic articular rheumatic pain, neuralgia, neuropathy, hyperesthesia dolorosa, nerve injury, ischemic diseases, neurodegeneration, apoplexy, incontinence and/or inflammatory diseases.

COPYRIGHT: (C)2003,JPO

Data supplied from the esp@cenet database - Worldwide